ASBP

Aspire Biopharma Holdings, Inc. (ASBP) - Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company focused on developing novel sublingual delivery mechanisms for known drugs. The reporting period is defined by the consummation of a business combination with PowerUp Acquisition Corp. on February 17, 2025, which was accounted for as a reverse recapitalization. The Company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Debt and Liquidity: The Company holds significant debt obligations, including $3,175,354 in convertible notes, $1,878,268 in subscription agreement loans, and $1,211,346 in related party notes payable. Cash flow from financing activities provided $3,094,438, primarily from the issuance of convertible notes and recapitalization proceeds.

Material Changes vs. Prior Period

• Explosion in Operating Expenses: General and administrative expenses surged to $15.07 million from $132,804 in the prior year. This increase is primarily driven by a one-time stock-based compensation charge of $14.13 million related to shares issued to an advisory firm upon the closing of the business combination.
• Debt Assumption: Total liabilities increased significantly due to the assumption of liabilities from the business combination and new financing arrangements, including convertible debentures and subscription loans.
• Share Structure: Following the reverse recapitalization, the number of Class A common shares outstanding increased from approximately 27.6 million to 48.9 million.
• Net Loss: Net loss increased by approximately $15.7 million year-over-year, largely attributable to the non-cash stock-based compensation and increased interest expenses on new debt.

Outlook, Risks, and Contingencies

Going Concern: Management has determined that the Company's liquidity condition raises substantial doubt about its ability to continue as a going concern for twelve months from the date of the filing. The Company has an accumulated deficit of $18.7 million and a working capital deficit of $6.9 million. Future operations depend on raising additional capital through equity issuances.

Nasdaq Compliance: On April 16, 2025, the Company received notices from Nasdaq regarding deficiencies in the Market Value of Listed Securities (MVLS) and Minimum Bid Price ($1.00). The Company has a 180-day period to regain compliance or face delisting.

Debt Settlement: The Company received default notices in April 2025 regarding late filings. A settlement agreement was reached on April 24, 2025, curing the defaults and extending maturity dates of key notes to August and September 2025. This settlement required the issuance of 625,000 shares to a lender.

Product Pipeline: The Company is conducting a bioavailability study for its high-dose sublingual aspirin product ("Instaprin"), expected to conclude by June 30, 2025. Other products in development include sublingual melatonin, vitamins, testosterone, and semaglutide.

Investor Verification Checklist

• Going Concern Status: Verify the Company's ability to secure additional financing to cover the $6.9 million working capital deficit and avoid insolvency.
• Nasdaq Delisting Risk: Monitor the Company's progress in meeting the $50 million MVLS and $1.00 bid price requirements within the 180-day compliance window.
• Debt Maturities: Review the terms of the convertible notes and related party loans, noting the extended maturity dates (August/September 2025) and the potential for further dilution upon conversion.
• Stock-Based Compensation: Confirm the impact of the $14.13 million non-cash expense on future quarters and whether similar one-time charges are expected.
• Clinical Trial Progress: Track the results of the aspirin bioavailability study (Trial 1) ending June 30, 2025, as this is critical for future revenue generation.